Lanadelumab And Cardiovascular Risk: Findings From The Phase 3 HELP Study

被引：0
|
作者：
Sexton, Daniel J. [1 ]
Brown, Nancy J. [2 ]
Lumry, William R. [3 ]
Gower, Richard G. [4 ]
Hao, James [1 ]
Lu, Peng [1 ]
Zafra, Heidi T. V. [5 ]
机构：
[1] Shire, Lexington, MA USA
[2] Vanderbilt Univ, Med Ctr, Nashville, TN USA
[3] AARA Res Ctr, Dallas, TX USA
[4] Marycliff Clin Res, Spokane, WA USA
[5] Med Coll Wisconsin, Milwaukee, WI 53226 USA
来源：
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2019年 / 143卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
136
引用
收藏
页码：AB46 / AB46
页数：1
相关论文
共 50 条
  • [21] Increased Response to Higher Dose Lanadelumab in Hereditary Angioedema Patients: Exploratory Findings From the HELP and HELP OLE Studies
    Jacobs, Joshua S.
    Bernstein, Jonathan
    Davis-Lorton, Mark
    Li, H. Henry
    Soteres, Daniel F.
    Nurse, Christina
    Paes, Kim
    Sexton, Daniel J.
    Longhurst, Hilary
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2019, 143 (02) : AB39 - AB39
  • [22] Lanadelumab is well-tolerated and effective across patient subgroups: Findings from the HELP open-label extension study
    Maurer, M.
    Lumry, W. R.
    Li, H. H.
    Jacobs, J.
    Soteres, D.
    Lu, P.
    Hao, J.
    Banerji, A.
    ALLERGY, 2020, 75 : 60 - 60
  • [23] Use of short term prophylaxis during treatment with lanadelumab does not impact the risk of an attack: Analysis of data from the HELP study and HELP OLE
    Staubach, P.
    Soteres, D.
    Aygoren-Pursun, E.
    Tachdjian, R.
    Lumry, W.
    Hao, J.
    Lu, P.
    Jacobs, J.
    ALLERGY, 2019, 74 : 211 - 212
  • [24] Effectiveness of lanadelumab for preventing hereditary angioedema attacks: Subgroup analyses from the HELP study
    Johnston, Douglas T.
    Busse, Paula J.
    Riedl, Marc A.
    Maurer, Marcus
    Anderson, John
    Nurse, Christina
    Inhaber, Neil
    Yu, Ming
    Banerji, Aleena
    CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (10) : 1391 - 1395
  • [25] Consistent Lanadelumab Treatment Effect In Patients With Hereditary Angioedema (HAE) Regardless Of Baseline Attack Frequency In The Phase 3 HELP Study
    Riedl, Marc A.
    Tachdjian, Raffi
    Schranz, Jennifer
    Nurse, Christina
    Bernstein, Jonathan A.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB47 - AB47
  • [26] Main findings from the prospective Cardiovascular Risk in Young Finns Study
    Juonala, Markus
    Viikari, Jorma S. A.
    Raitakari, Olli T.
    CURRENT OPINION IN LIPIDOLOGY, 2013, 24 (01) : 57 - 64
  • [27] Efficacy of lanadelumab in patients switching from long-term prophylaxis with C1-inhibitor (C1-INH): results from the phase 3 HELP Study
    Johnston, Douglas T.
    Anderson, John T.
    Schranz, Jennifer
    Nurse, Christina
    Cicardi, Marco
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB47 - AB47
  • [28] Long-term effectiveness and safety of lanadelumab in the US and Canada: Findings from the EMPOWER Study
    Johnston, Douglas
    Anderson, John
    Brouwer, Emily
    Andriotti, Tomas
    Fei, Kezhin
    Busse, Paula
    Bernstein, Jonathan
    Zuraw, Bruce
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB165 - AB165
  • [29] Cardiovascular risk in atypical versus melancholic depression: Findings from the NESDA study
    Penninx, Brenda
    PSYCHONEUROENDOCRINOLOGY, 2015, 61 : 6 - 7
  • [30] Attack-free status during steady state of lanadelumab treatment in patients with -hereditary angioedema: findings from the HELP open-label extension study
    Magerl, M.
    Johnston, D. T.
    Lumry, W. R.
    Bernstein, J. A.
    Nurse, C.
    Yu, M.
    Riedl, M. A.
    ALLERGOLOGIE, 2022, 45 (08) : 606 - 606
12345